Paper29784646
Latest developments in MUC1 immunotherapy.
Taylor-Papadimitriou J and 3 others. Biochem Soc Trans, 2018. Cited by 113 papers, by iCite.
Cite this record
ConductScience Library. Latest developments in MUC1 immunotherapy. Papers, record 29784646. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29784646
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Immunotherapy | Major topic |
| Mucin-1 | Major topic |
| Neoplasms | Major topic |
| Antimetabolites, Antineoplastic | |
| Clinical Trials as Topic | |
| Combined Modality Therapy | |
| Deoxycytidine | |
| Glycosylation | |
| Humans | |
| Tumor Microenvironment | |
| Gemcitabine |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| MC_PC_16048 | Medical Research Council | United Kingdom | PubMed | |
| MR/R000026/1 | Medical Research Council | United Kingdom | PubMed |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT04239105 | Detection of Circulating Tumor Cells in Breast Cancer Patients Using a Novel Microfluidic and Raman Spectrum Device | Background |
Source ClinicalTrials.gov
References60
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 8969192 | Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells. | J Biol Chem | 1996 | https://conductscience.org/library/papers/8969192 | PubMed |
| 2 | 19711367 | MUC1 is a substrate for gamma-secretase. | J Cell Biochem | 2009 | https://conductscience.org/library/papers/19711367 | PubMed |
| 3 | 28555079 | MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs. | Leukemia | 2017 | https://conductscience.org/library/papers/28555079 | PubMed |
| 4 | 21189474 | Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. | Mol Ther | 2011 | https://conductscience.org/library/papers/21189474 | PubMed |
| 5 | 8046349 | Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. | J Exp Med | 1994 | https://conductscience.org/library/papers/8046349 | PubMed |
| 6 | 12519300 | Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration. | Immunology | 2003 | https://conductscience.org/library/papers/12519300 | PubMed |
| 7 | 27285281 | A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas. | Eur J Cancer | 2016 | https://conductscience.org/library/papers/27285281 | PubMed |
| 8 | 18354214 | Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. | J Immunol | 2008 | https://conductscience.org/library/papers/18354214 | PubMed |
| 9 | 15115750 | Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1). | Glycobiology | 2004 | https://conductscience.org/library/papers/15115750 | PubMed |
| 10 | 1709586 | Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. | Cancer Res | 1991 | https://conductscience.org/library/papers/1709586 | PubMed |
| 11 | 16446329 | Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. | J Clin Oncol | 2006 | https://conductscience.org/library/papers/16446329 | PubMed |
| 12 | 22580612 | MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. | Oncogene | 2013 | https://conductscience.org/library/papers/22580612 | PubMed |
| 13 | 25998800 | Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model. | Cancer Immunol Immunother | 2015 | https://conductscience.org/library/papers/25998800 | PubMed |
| 14 | 9600956 | Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. | Proc Natl Acad Sci U S A | 1998 | https://conductscience.org/library/papers/9600956 | PubMed |
| 15 | 10197628 | The breast cancer-associated MUC1 gene generates both a receptor and its cognate binding protein. | Cancer Res | 1999 | https://conductscience.org/library/papers/10197628 | PubMed |
| 16 | 16485130 | PankoMab: a potent new generation anti-tumour MUC1 antibody. | Cancer Immunol Immunother | 2006 | https://conductscience.org/library/papers/16485130 | PubMed |
| 17 | 26800384 | A Synthetic Glycopeptide Vaccine for the Induction of a Monoclonal Antibody that Differentiates between Normal and Tumor Mammary Cells and Enables the Diagnosis of Human Pancreatic Cancer. | Angew Chem Int Ed Engl | 2016 | https://conductscience.org/library/papers/26800384 | PubMed |
| 18 | 6273328 | Differentiation antigens expressed by epithelial cells in the lactating breast are also detectable in breast cancers. | Int J Cancer | 1981 | https://conductscience.org/library/papers/6273328 | PubMed |
| 19 | 24188672 | Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1. | Immunotherapy | 2013 | https://conductscience.org/library/papers/24188672 | PubMed |
| 20 | 24995129 | A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer. | J Immunother Cancer | 2014 | https://conductscience.org/library/papers/24995129 | PubMed |
Cited by81
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 113 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42461956 | Mucin expression in pancreatic ductal adenocarcinoma cell lines in 2D and 3D cultures: A proteomic and immunocytochemical analysis. | PLoS One | 2026 | https://conductscience.org/library/papers/42461956 | PubMed |
| 41516394 | Tumour-Associated MUC1 Exerts Multiple Effects on Cholesterol and Lipid Metabolism-A Potential Pathogenic Effector of Atherosclerosis in Cancer. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41516394 | PubMed |
| 41154387 | The Role of MUC1 in Gastric Cancer Development. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41154387 | PubMed |
| 41150755 | Dendritic Cell Immunotherapy for Solid Tumors: Advances in Translational Research and Clinical Application. | Curr Issues Mol Biol | 2025 | https://conductscience.org/library/papers/41150755 | PubMed |
| 40711726 | The network map of mucin 1 mediated signaling in cancer progression and immune modulation. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40711726 | PubMed |
| 40649198 | The Role of Glycans in Human Immunity-A Sweet Code. | Molecules | 2025 | https://conductscience.org/library/papers/40649198 | PubMed |
| 40443897 | Enhancing Cancer Vaccine Efficacy: Backbone Modification with β‑Amino Acids Alters the Stability and Immunogenicity of MUC1-Derived Glycopeptide Formulations. | JACS Au | 2025 | https://conductscience.org/library/papers/40443897 | PubMed |
| 40221891 | Structure of the Fab fragment of a humanized 5E5 antibody to a cancer-specific Tn-MUC1 epitope. | Acta Crystallogr D Struct Biol | 2025 | https://conductscience.org/library/papers/40221891 | PubMed |
| 40179083 | Prognostic implications of MUC1 and XBP1 concordant expression in multiple myeloma: A retrospective study. | PLoS One | 2025 | https://conductscience.org/library/papers/40179083 | PubMed |
| 40148706 | Improved breast cancer diagnosis using a CA15-3 capture antibody-lectin sandwich assay. | Breast Cancer Res Treat | 2025 | https://conductscience.org/library/papers/40148706 | PubMed |
| 39213364 | Multi-armored allogeneic MUC1 CAR T cells enhance efficacy and safety in triple-negative breast cancer. | Sci Adv | 2024 | https://conductscience.org/library/papers/39213364 | PubMed |
| 39095059 | O-glycosylation of IgA1 and the pathogenesis of an autoimmune disease IgA nephropathy. | Glycobiology | 2024 | https://conductscience.org/library/papers/39095059 | PubMed |
| 38943923 | Plasma extracellular vesicles proteomics in meningioma patients. | Transl Oncol | 2024 | https://conductscience.org/library/papers/38943923 | PubMed |
| 38660669 | Establishment of a cholangiocarcinoma risk evaluation model based on mucin expression levels. | World J Gastrointest Oncol | 2024 | https://conductscience.org/library/papers/38660669 | PubMed |
| 38611013 | Targeting Siglec-Sialylated MUC1 Immune Axis in Cancer. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38611013 | PubMed |
| 38540735 | The Role of MUC1 in Renal Cell Carcinoma. | Biomolecules | 2024 | https://conductscience.org/library/papers/38540735 | PubMed |
| 38274250 | Structure-Guided Approach for the Development of MUC1-Glycopeptide-Based Cancer Vaccines with Predictable Responses. | JACS Au | 2024 | https://conductscience.org/library/papers/38274250 | PubMed |
| 38164273 | Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy. | J Cancer | 2024 | https://conductscience.org/library/papers/38164273 | PubMed |
| 38140114 | Enhancing T Cell and Antibody Response in Mucin-1 Transgenic Mice through Co-Delivery of Tumor-Associated Mucin-1 Antigen and TLR Agonists in C3-Liposomes. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/38140114 | PubMed |
| 38123235 | Selection of potential targets for stratifying congenital pulmonary airway malformation patients with molecular imaging: is MUC1 the one? | Eur Respir Rev | 2023 | https://conductscience.org/library/papers/38123235 | PubMed |
Genes19
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29784646
GET https://conductscience.org/api/papers/v1/29784646/references?page=2